Hungund Basalingappa L, Basavarajappa Balapal S
New York State Psychiatric Institute, New York 10032, USA.
Ann N Y Acad Sci. 2004 Oct;1025:515-27. doi: 10.1196/annals.1316.064.
This review presents the remarkable research during the past several years indicating that some of the pharmacological and behavioral effects of alcohol, including alcohol drinking and alcohol-preferring behavior, are mediated through one of the most abundant neurochemical systems in the central nervous system, the endocannabinoid signaling system. The advances, with the discovery of specific receptors and the existence of naturally occurring cannabis-like substances in the mammalian system and brain, have helped in understanding the neurobiological basis for drugs of abuse, including alcoholism. The cDNA and genomic sequences encoding G-protein-coupled cannabinoid receptors (CB1 and CB2) from several species have now been cloned. This has facilitated discoveries of endogenous ligands (endocannabinoids). To date, two fatty acid derivatives characterized to be arachidonylethanolamide and 2-arachidonylglycerol have been isolated from both nervous and peripheral tissues. Both these compounds have been shown to mimic the pharmacological and behavioral effects of Delta9-tetrahydrocannabinol, the psychoactive component of marijuana. The involvement of the endocannabinoid signaling system in tolerance development to drugs of abuse, including alcohol, were unknown until recently. Studies from our laboratory demonstrated for the first time the downregulation of CB1 receptor function and its signal transduction by chronic alcohol. The observed downregulation of CB1 receptor binding and its signal transduction results from the persistent stimulation of receptors by the endogenous CB1 receptor agonists arachidonylethanolamide and 2-arachidonylglycerol, the synthesis of which is increased by chronic alcohol treatment. The deletion of CB1 receptor has recently been shown to block voluntary alcohol intake in mice, which is consistent with our previous findings where the DBA/2 mice known to avoid alcohol intake had significantly reduced brain CB1 receptor function. These findings suggest a role for the CB1 receptor gene in excessive alcohol drinking behavior and development of alcoholism. Ongoing investigations may lead to the development of potential therapeutic agents to modulate the endocannabinoid signaling system, which will be helpful for the treatment of alcoholism.
本综述介绍了过去几年间的显著研究成果,这些研究表明,酒精的某些药理和行为效应,包括饮酒及嗜酒行为,是通过中枢神经系统中最丰富的神经化学系统之一——内源性大麻素信号系统介导的。随着特定受体的发现以及哺乳动物系统和大脑中天然存在的类大麻素物质的发现,这些进展有助于理解包括酒精中毒在内的滥用药物的神经生物学基础。目前已克隆出多个物种编码G蛋白偶联大麻素受体(CB1和CB2)的cDNA和基因组序列。这促进了内源性配体(内源性大麻素)的发现。迄今为止,已从神经组织和外周组织中分离出两种脂肪酸衍生物,分别鉴定为花生四烯酸乙醇胺和2-花生四烯酸甘油。这两种化合物均已被证明可模拟大麻中具有精神活性的成分Δ9-四氢大麻酚的药理和行为效应。直到最近,内源性大麻素信号系统在包括酒精在内的滥用药物耐受性发展中的作用仍不明确。我们实验室的研究首次证明,慢性酒精会导致CB1受体功能及其信号转导下调。观察到的CB1受体结合及其信号转导的下调是由于内源性CB1受体激动剂花生四烯酸乙醇胺和2-花生四烯酸甘油对受体的持续刺激所致,而慢性酒精处理会增加它们的合成。最近的研究表明,敲除CB1受体会阻止小鼠自愿饮酒,这与我们之前的研究结果一致——已知避免饮酒的DBA/2小鼠脑内CB1受体功能显著降低。这些发现表明CB1受体基因在过度饮酒行为和酒精中毒发展中起作用。正在进行的研究可能会促成调节内源性大麻素信号系统的潜在治疗药物的开发,这将有助于治疗酒精中毒。